Everlywell, an at-home lab testing company, is partnership with Jona, an AI-powered gut microbiome company, to bring a gut microbiome test to consumers nationwide.
Everlywell is a direct-to-consumer company that sells tests in all 50 states for everyday health, digestive health, sexual health, and hormonal health. It also offers telehealth appointments with clinicians and partners with health plans and employers.
Through the partnership with Jona, customers will be able to access Jona’s at-home gut microbiome test directly on Everlywell’s platform for $399, compared to the usual price of $485.
The test identifies bacteria, viruses and fungi in the microbiome, then provides results based on thousands of scientific studies, identifying associations between the patient’s microbiome and various conditions like Crohn’s disease or psoriasis. It will also offer personalized recommendations on diet, supplements and lifestyle changes to improve gut health.
“Jona analyzes the microbiome with deep strain-level resolution, uses AI to connect these results to the most recent research, and applies our simulation-based digital twin to identify the most effective solutions for a person’s biology,” said Leo Grady, founder and CEO of Jona. “This way we ensure that consumers receive information that is not just descriptive; they are also actionable and evidence-based. »
According to Everlywell, the gut microbiome is one of the “next frontiers of consumer-initiated testing.”
“We are receiving a lot of interest from innovative diagnostic companies who want to partner with us because of the breadth of the Everlywell platform: our consumer DTC site, our network of clinicians and genetic counselors in 50 states, our deep experience working with health plans,” said Matt O’Connor, general manager of Everlywell’s consumer division. “In Jona’s case, we are excited to partner with one of the most innovative companies in the microbiome space, combining their technology with Everlywell’s consumer platform and clinical network to expand access to potentially game-changing insights into the microbiome’s impact on digestion, immunity, metabolism, and more.
This partnership is part of the framework 60 to 70 million Americans are affected by digestive diseases, including chronic constipation, gastrointestinal infections, and inflammatory bowel disease. Jona aims to make the gut microbiome a “standard part of how healthcare is understood and managed,” and working with Everlywell allows it to scale to millions of consumers, Grady said.
“Our vision is to make microbiome testing as common as blood testing, not just something niche or experimental,” he said. “Part of realizing this vision is making advanced microbiome insights accessible on a national and then global scale. Everlywell has already demonstrated how to reach millions of people with at-home testing, and together we want to bring a new level of depth and personalization to that experience.”
Photo: mikdam, Getty Images